Huang Richard S P, Lee Jessica K, Lofgren Katherine T
Foundation Medicine, Inc., Cambridge, MA, United States.
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyae293.
The use of biomarker testing to inform treatment decisions has emerged as a standard of care in multiple cancer types. However, the rates of patients with genomic testing results in hand to inform treatment decision-making remain variable. Here, we studied the impact of comprehensive genomic profiling (CGP) on clinical trial enrollment rates in patients with advanced-stage non-small cell lung, colorectal, breast, and prostate cancer using a real-world clinicogenomic database. On average, clinical trial enrollment in the therapy line immediately after CGP report receipt was 5.4%, which represents a 3.0 percentage point increase compared to therapy lines preceding CGP report receipt, supporting a meaningful association between CGP report availability and increased clinical trial enrollment.
使用生物标志物检测来指导治疗决策已成为多种癌症类型的治疗标准。然而，手握基因组检测结果以指导治疗决策的患者比例仍然存在差异。在此，我们使用一个真实世界的临床基因组数据库，研究了全面基因组分析（CGP）对晚期非小细胞肺癌、结直肠癌、乳腺癌和前列腺癌患者临床试验入组率的影响。平均而言，在收到CGP报告后的紧接着的治疗线中，临床试验入组率为5.4%，与收到CGP报告之前的治疗线相比增加了3.0个百分点，这支持了CGP报告的可获得性与临床试验入组率增加之间存在有意义的关联。
